Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (461-470 of 551) with videos related to

Pageof 56
Sort By:
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Molecular Therapy. Methods & Clinical Development|January 21, 2021
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized miceDaniel Stone, Kelly R Long, Michelle A Loprieno, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)Stephen Walsh, William O Hahn, Wilton B Williams, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Pageof 56

Showing results (461-470 of 551) with videos related to

Sort By:
Pageof 56
JCI Insight|May 22, 2020
Robust antibody and cellular responses induced by DNA-only vaccination for HIVStephen C De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Molecular Therapy. Methods & Clinical Development|January 21, 2021
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized miceDaniel Stone, Kelly R Long, Michelle A Loprieno, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)Stephen Walsh, William O Hahn, Wilton B Williams, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Pageof 56